Analyst Ratings for Axsome Therapeutics
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has received mostly bullish ratings from analysts in the last quarter, with 5 bullish, 2 somewhat bullish, and 1 indifferent rating. The average 12-month price target for the stock, according to 8 analysts, is $118.62, a decrease of 3.4% from the previous average of $122.80.
September 25, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has received mostly positive ratings from analysts, which could potentially boost investor confidence and the stock price in the short term.
Analyst ratings often influence investor sentiment and can impact a stock's price. In this case, the majority of the ratings for Axsome Therapeutics are bullish, which could lead to increased investor confidence and a potential rise in the stock's price in the short term. However, the decrease in the average price target could temper this effect somewhat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100